Clinical Trial Update: Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating carfilzomib, cyclophosphamide, and dexamethasone in transplant-eligible, high-risk newly diagnosed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• carfilzomib, cyclophosphamide, dexamethasone

Snippet

Sponsor: Singapore General Hospital | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED